Trastuzumab Has Radically Improved Prognosis for HER2+ Breast

Trastuzumab and pertuzumab trastuzumab Trastuzumab deruxtecan is a HER2 directed antibody-drug conjugate The humanized IgG1 monoclonal antibody is linked to trastuzumab Trastuzumab deruxtecan Trastuzumab deruxtecan, sold under the brand name Enhertu, is an antibody-drug conjugate consisting of the humanized monoclonal

trastuzumab trastuzumab Early breast cancer Herceptin is indicated for the treatment of patients with HER2-positive early breast cancer: following surgery